-
Astrazeneca PLC
-
Sector
Health Care
-
Industry
Pharmaceuticals
-
Company web
Link
-
Employees
Full Time Employees: 59,700
-
Executives
- Leif Johansson
- Pascal Soriot
- Marc Dunoyer
- Fiona Cicconi
- Sean Bohen
- Pam Cheng
- Ruud Dobber
- Bahija Jallal
- Mark Mallon
- Menelas Pangalos
-
Company address
- 1 Francis Crick Avenue
- Cambridge, CB2 0AA
- United Kingdom
- 1-44 20 3749 5000
-
Investor Relation Site
Link
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. It has collaboration agreements with Valeant Holdings Ireland, Eli Lilly and Company, FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., Moderna Therapeutics, and Takeda Pharmaceutical Company Limited; definitive agreement with Foundation Medicine, Inc.; a clinical trial collaboration agreement with G1 Therapeutics, Inc.; collaboration and license agreement with Celgene International Sarl; and a license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Astrazeneca PLC: Slide deck
- AZN - Q3 Investor Presentation 9 Nov 2017: Slides deck
- AZN - Q3 Investor Presentation 10 Nov 2016: Slides deck
- AZN - Q2 Investor Presentation 27 July 2017: Slides deck
- AZN - Q2 Investor Presentation 26 July 2016: Slides deck
- AZN - Q1 Investor Presentation 27 April 2017: Slides deck